Alginate-antacid combinations: Raft formation and gastric retention studies

Drug Development and Industrial Pharmacy

Volumn 36, Issue 5, 2010, Pages 614-623

  Hampson, Frank C ^a   Jolliffe, Ian G ^b   Bakhtyari, Arash ^c   Taylor, Glyn ^c   Sykes, John ^b   Johnstone, Lesley M ^b   Dettmar, Peter W ^a  

^a Technostics Limited   (United Kingdom)

^b RECKITT BENCKISER   (United Kingdom)

^c Simbec Scintigraphics Ltd   (United Kingdom)

Author keywords

Alginate; Antacid; Formulation; Gastric retention; Gastroesophageal reflux; Raft

Indexed keywords

ALGINIC ACID; ANTACID AGENT; GASVISON DOUBLE ACTION LIQUID; GASVISON LIQUID; GAVISCON; GAVISCON LIQUID EXTRA STRENGTH; GAVISCON LIQUID REGULAR STRENGTH; MYLANTA; MYLANTA HEARTBURN RELIEF; RENNIE; RENNIE LIQUID RELIEF; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG RETENTION; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ALGINATES; ANTACIDS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG COMBINATIONS; FOOD-DRUG INTERACTIONS; GASTROESOPHAGEAL REFLUX; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; MALE; STOMACH; YOUNG ADULT;

EID: 77952599708     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903388290     Document Type: Article

References (20)

1. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. (2000). Review article: Alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther, 14: 669-90.
2. Washington N, Washington C, Wilson CG, Davis SS. (1986b). What is 'liquid Gaviscon'? A comparison of four international formulations. Int J Pharm, 34: 105-9.
3. Lambert JR, Korman MG, Nicholson L, Chan JG. (1990). In-vivo anti-reflux and raft properties of alginates. Aliment Pharmacol Ther, 4: 615-22.
4. Washington N, Greaves JL, Iftikhar SY. (1992). A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension. Aliment Pharmacol Ther, 6: 579-88.
5. Washington N, Washington C, Wilson CG. (1987). Gastric distribution and residence time of two anti-reflux formulations. Int J Pharm, 39: 163-71.
6. Washington N, Washington C, Wilson CG, Davis SS. (1986a). The effect of inclusion of aluminium hydroxide in alginate containing raft-forming antacids. Int J Pharm, 28: 139-43.
7. Davies NM, Farr SJ, Kellaway IW, Taylor G, Thomas M. (1994). A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions. Int J Pharm, 105: 97-101.
8. Hampson FC, Farndale A, Strugala V, Sykes J, Jolliffe IG, Dettmar PW. (2005). Alginate rafts and their characterisation. Int J Pharm, 294: 137-47.
9. Hampson FC, Banks A, Jolliffe IG, Dettmar PW. (2002). Raft resilience in alginate anti-reflux products. J Pharm Pharmacol, 54: S30-1.
10. Dettmar PW, Little SL, Baxter T. (2005). The effect of omeprazole pre-treatment on rafts formed by reflux suppressant tablets containing alginate. J Int Med Res, 33: 301-8.
11. Taylor G, Warren SJ, Kellaway IW, Patel B, Little SL. (1997). Gastric residence of Gaviscon advance and liquid Gaviscon in healthy volunteers. J Pharm Pharmacol, 49: 73.
12. BP. (2007). Alginate raft-forming oral suspension. In: British pharmacopoeia. London: The Stationary Office.
13. Martin JL, Beck WJ, McDonald AP, Carlson GM, Mathias, JR. (1983). 99mTc-labeled solid-phase meal: A quantitative clinical measurement of human gastric emptying. J Clin Gastroenterol, 5: 315-9.
14. Velasco N, Allen FH, Hill, L. D. (1982). A simple solid-phase marker for gastric emptying studies. Br J Radiol, 55: 533-4.
15. Hardy JG, Perkins AC. (1985). Validity of the geometric mean correction in the quantification of whole bowel transit. Nucl Med Commun, 6: 217-24.
16. Tytgat GN, Simoneau G. (2006). Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspensions. Aliment Pharmacol Ther, 23: 759-65.
17. Washington N, Greaves JL, Wilson CG. (1990). Effect of time of dosing relative to a meal on the raft formation of an anti-reflux agent. J Pharm Pharmacol, 42: 50-3.
18. Washington N, Wilson CG, Williams DL, Robertson C. (1993). An investigation into the effect of cimetidine pre-treatment on raft formation of an anti-reflux agent. Aliment Pharmacol Ther, 7: 553-9.
19. Washington N, Bell JS, Lamont G, Wilson CG, Toselli D. (1998). An investigation into the raft-forming properties of Topaal Whip, a novel anti-reflux agent, in healthy volunteers. STP Pharm Sci, 8: 123-6.
20. May HA, Wilson CG, Hardy JG. (1984). Monitoring radiolabelled antacid preparations in the stomach. Int J Pharm, 170: 169-76.